01/28/2026
š§ Does age change how we fight brain cancer?
New insights on immunotherapy & glioblastoma
š„ Hot off the press!
Our latest study in takes on a criticalāand often overlookedāquestion in glioblastoma (GBM):
š What happens when immunotherapy meets the aging immune system?
𧬠Why this matters
Immunotherapy works by training your own immune system to attack cancer.
But as we age, our immune system changes (immunosenescence). GBM is more common in older adultsāyet most clinical trials focus on younger patients.
š¤ The big question
Does immunotherapy work the same way across ages?
š What we found
By analyzing data across multiple studies (a meta-analysis), we discovered that an aging immune system creates a different tumor environmentāone that can make it harder for current immunotherapies to fully activate immune cells.
š” The takeaway
Immunotherapy isnāt failing older patientsābut a one-size-fits-all approach may be. Different immune ages may need different strategies.
š Looking ahead
This is a call to design smarter, age-aware clinical trialsāso breakthroughs benefit everyone, not just the young.
š§ To beat brain cancer, we must treat the tumor and the person itās in.
Personalized care starts with understanding the immune systemāat every age. šŖš§¬
š Huge congratulations to all the co-authors!
Immunotherapy has yet to meaningfully translate to more complex solid tumors, such as Glioblastoma (GBM), which is a disease of old age with a median diagn